
Ortoma Q3'2024 - Positive outlook and finances in focus

Redeye makes some revisions based on the Q3 report. The milestones did not arrive as we expected in the quarter; however, the path to receive the rest is set and just a question of timing, and we expect that they will receive the almost total amount by mid-2025e. The progress continues, in our view, even if the timing of the sales is tricky as it is still early in the commercialization process. We maintain our fair value range and Base case at SEK 20 (20) per share.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Ortoma Q3'2024 - Positive outlook and finances in focus](#)